RT @drdavidliew: DVT/PE has been the sticking point for baricitinib in RA. DVT/PE risk in integrated safety analysis &g
Tweet Content
DVT/PE has been the sticking point for baricitinib in RA.
DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either.
Every drug has pros/cons; it's how we manage risk that counts...
#ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ
Show on Archive Page
On
Display in Search Results
On